On May 4, 2012, Wang Yingguang, Deputy Director of Beijing Municipal Commission of Economy and Information Technology, Sun Xuejun, Deputy Director of Biomedical Division, and Peng Xingtao, Deputy Ddirector of Beijing Huairou Commission of Economy and Information Technology, came to our company to conduct a site inspection. The Beijing Honglin pharmaceutical company operation situation of the first quarter, forecast of economic operation for the whole year, policy and the fund support required in the next step of development and operation were investigated. Mr. Wei Dong, person in charge of the enterprise, introduced the Beijing Honglin pharmaceutical company status, product situation, the company’s overall development direction, and the key jobs of the company in 2012. The company’s osmotic pump preparation and market situation of this year were emphasized as key points.

Deputy Director Wang affirmed the achievements obtained by Beijing Honglin pharmaceutical via actively increasing science and technology investment, continuously researching and developing new production, and paying attention to technical innovation. Beijing Honglin pharmaceutical company osmotic pump controlled-release technology platform and commercialization impressed everyone. Deputy Director Wang indicated that strengthening independent innovation, comprehensively depending on scientific and technological progress are the key points of enterprise development. He hoped that the enterprise could continuously convert the characteristics of the company to enterprise’s advantage, increase related investment and scientific management, and make contributions to the development of Beijing pharmaceutical enterprises during the twelfth five-year. Meanwhile, he expressed that he is willing to provide necessary support and help for the enterprise’s development.